Table 3.
Cost-effectiveness of RZV vs no vaccination for various vaccination starting ages: assuming a fixed cohort of 1 million with a vaccine coverage of 40%
| Age | 50 YOA | 60 YOA | 65 YOA | 70 YOA |
|---|---|---|---|---|
| HZ cases avoided | 68,042 | 65,410 | 60,735 | 47,594 |
| PHN cases avoided | 11,087 | 11,919 | 11,700 | 9,568 |
| Total costs (discounted) | 53,716,953 | 54,325,317 | 56,876,134 | 64,859,931 |
| QALYs gained (discounted) | 1,818 | 2,127 | 2,178 | 1,871 |
| ICER | €29,547/ QALY |
€25,536/ QALY |
€26,116/ QALY |
€34,663/ QALY |
HZ: herpes zoster; PHN: postherpetic neuralgia; RZV: recombinant zoster vaccine; YOA: years of age; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio.